Consensus Bio-Rad Laboratories, Inc.

Stocks

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 16:00:02 2026-06-11 EDT			5-day change	1st Jan Change
292.44 ^USD	+0.49%		-4.89%	-3.48%

06-03	Bio-Rad Laboratories, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:45 AM
05-19	Bio-Rad Laboratories, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 08:30 AM

Evolution of the Average Target: Bio-Rad Laboratories, Inc.

Evolution of the Target Price: Bio-Rad Laboratories, Inc.

Changes in Analyst Recommendations: Bio-Rad Laboratories, Inc.

c5249a720ce240b0fc.cd4ocH7cuFshH4Jaqmo7o7a3eG_5vh0PcODDR_D4QRk.HolcJE6vjTJxaehp5RJ56eXUKiS8iWhoHKuRMYmIE15JmUEcR6X2HBlN4Q~67888a3e8997864e237fe70cfa5d59b4

Analysts' recommendations: Bio-Rad Laboratories, Inc.

05-15	Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says	MT
04-07	Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375	MT
02-13	UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating	MT
25-10-30	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
25-09-03	RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating	MT
25-08-01	UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating	MT
25-08-01	RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating	MT
25-07-01	RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating	MT
25-05-02	UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating	MT
25-05-02	RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating	MT
25-04-08	RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating	MT
25-02-14	UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating	MT
25-02-14	RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating	MT
25-02-04	RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating	MT
24-12-09	RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating	MT
24-10-31	UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating	MT
24-10-01	Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350	MT
24-09-13	RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating	MT
24-08-28	Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target	MT
24-08-02	Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300	MT
24-08-02	UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating	MT
24-08-02	RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating	MT
24-06-24	RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	MT
24-05-08	UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating	MT
24-05-08	RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIO-RAD LABORATORIES, INC.					+2.06%
	ABBOTT LABORATORIES					+31.54%
	MEDTRONIC PLC					+22.84%
	CENCORA, INC.					+24.66%
	HOYA CORPORATION					+17.13%
	BECTON, DICKINSON AND COMPANY					+22.63%
	MEDLINE INC.					+39.98%
	DEXCOM, INC.					+13.24%
	WEST PHARMACEUTICAL SERVICES, INC.					+8.42%
	TERUMO CORPORATION					+28.32%
	Average					+21.08%
	Weighted average by Cap.					+24.77%